Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NEnHOpZHfW6ldHnvckBCe3OjeR?= NXzSZ21yOC55zszN NHziPVYzPGh? M3fieYV1cGGwb3y= Mlvw[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? MWiyOVc5PzB5OR?=
TE13 MnTOSpVv[3Srb36gRZN{[Xl? NGrNbGIxNjQQvF2= MVmyOIg> MorweZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= NVPPb2RKOjV3N{m2OlU>
TE13 MWPBdI9xfG:|aYOgRZN{[Xl? M2T6TlAvO87:TR?= MX[yOIg> MXzpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v NED5NWozPTV5OU[2OS=>
MEFs NVvBZ5ZHTnWwY4Tpc44hSXO|YYm= NGG4XZc2|ryP NFW0bo0yPmh? NECyPWtqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? M2jYR|I2PDh{NkO0
SW480  M3nGb2Z2dmO2aX;uJGF{e2G7 NX7OOWtbOC5zzszN MWm0PIg> MWnEUXNQ MmX5doV3\XK|ZYOgSW1V NIq1[lAzPTR|NEm5Oy=>
PC3  NWm2TI5MTnWwY4Tpc44hSXO|YYm= Mn7INE4y|ryP M37vVlQ5cA>? NWK3TlJoTE2VTx?= NHH3O|Nz\X[ncoPld{BGVVR? MmTsNlU1OzR7OUe=
SW480  MUjGeY5kfGmxbjDBd5NigQ>? NE\yZZIxNjIQvF2= MV:0PIg> M3L5T2ROW09? NF\id2RifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MoqyNlU1OzR7OUe=
PC3  NHnyblRHfW6ldHnvckBCe3OjeR?= MXewMlHPxE1? MVG0PIg> M{T3eGROW09? NYH2dGJT[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u NYX5WYwzOjV2M{S5PVc>
SW480  MojvSpVv[3Srb36gRZN{[Xl? MY[wMlHPxE1? MlPjOFhp NV;6ZZY2TE2VTx?= NHLtdYhqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ NHfYRmkzPTR|NEm5Oy=>
PC3  MXXGeY5kfGmxbjDBd5NigQ>? M3z3OlAvOc7:TR?= NF6xWmw1QGh? M1rrS2ROW09? MYLpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MXmyOVQ{PDl7Nx?=
A431 MmOxRZBweHSxc3nzJGF{e2G7 M{D0SlIwOTBxNUCvNVAxdk1? NF;veIM1QGh? MnOxSG1UVw>? MXnpcohq[mm2czD0bIUh[2WubDDndo94fGh? MnLmNlU{PzFyNkm=
A431 M4TofmZ2dmO2aX;uJGF{e2G7 MnjHOVBvVQ>? NH3sS28zNzZxMUKvNlRp NFfzS41FVVOR NHPKe|Ri[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= NVjYdIdmOjV|N{GwOlk>
MDA-MB-231 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrpfpd{OC14MEDuUS=> MlG1NlRp NGXqPHFFVVOR MVHJR|UxKG:oIEGwNI5O MWqyOVE6Ojd{MR?=
MCF7 NYPZVFJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDSb2NPOC14MEDuUS=> MUeyOIg> NFXFOnNFVVOR NVTDRokzUUN3MDDv[kA4PW6P Mnq0NlUyQTJ5MkG=
SKOV-3 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnIdGMyNTFyzszN M1iwZVI1cA>? Mlu3SG1UVw>? Mo[wTWM2OCCxZjC1MlbPxE1? NHrlWFIzPTF4OUS5NS=>
A549 NUTCcWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTyTmFsOS1zMN88US=> NILDT|kzPGh? MmfmSG1UVw>? M3XGPWlEPTBib3[gN{4z|ryP M{LvVlI2OTZ7NEmx
SKOV-3 NX7EXJpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKwMlEuOc7:TR?= MUi0PIg> Mn:xSG1UVw>? NEfuS4NKSzVyIH;mJFAvP87:TR?= NIHHXm4zPTF4OUS5NS=>
A549 M4DXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqwMlEuOc7:TR?= Mo\XOFhp MV3EUXNQ NVnQXmFDUUN3MDDv[kAxNjJ6zszN NFLCWpIzPTF4OUS5NS=>
SKOV-3 NV\XcXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPUTHYxNjBzLUCuPe69VQ>? MnLkO|Jp MorISG1UVw>? M3PvO2lEPTBib3[gNE4{Os7:TR?= MUmyOVE3QTR7MR?=
A549 NHHDUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlAyNTBwOd88US=> M2\IT|czcA>? MXzEUXNQ Mor6TWM2OCCxZjCwMlA3|ryP M3XkWVI2OTZ7NEmx
HeLa M{frN2Z2dmO2aX;uJGF{e2G7 NGnSUlIzPTCwTR?= NIH6c5YyPmh? NWTCW25WTE2VTx?= NIr3O2NqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg MV:yOVEyPjZ6OB?=
CNE2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxNFAuPjBybl2= M3\qSFI1NzR6L{eybC=> NFexfYVqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH;qOoszPDl4OUmwNS=>
PC3 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNFAuOTByMH7N NVzQUGRsOjSq M3P1XmlEPTBib3[gN|Axdk1? MoHUNlQ5PTR4NUi=
LNCaP M12xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNFAuOTByMH7N NETkSXYzPGh? MXHJR|UxKG:oIEOwNI5O NXr4VYhMOjR6NUS2OVg>
HeLa  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3lNpUz|ryP MWK0PIg> M{W1WYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NXjpNIs6OjR6NE[xN|U>
HMEC-1  MVzGeY5kfGmxbjDBd5NigQ>? MmHnN|Axdk1? M17BW|I1cA>? MkTMbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> M4rzZlI1PzFyNkOx
HeLa NUO4SHlFTnWwY4Tpc44hSXO|YYm= NXnXOodwOW2P NYXtd5RsOC53aB?= M1HvPIFjd2yrc3jld{B1cGVidH;0ZYwhUESDQzDhZ5Rqfmm2eR?= M3PkfVI1PzB5NEe0
ACP02 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fW[FI2OC9|NUCvOVAxdk1? NVTzWG0zOjSq NVfyOJRD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MXGyOFY3QDV2Nx?=
ACP03 M2fsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPWfYwzPTBxM{WwM|UxOG6P M1XiSFI1cA>? M3PWZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MWeyOFY3QDV2Nx?=
U87 GBM NFHPSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxNFAwOzByL{WwNEBvVQ>? MY[3NkBp MW[xNFAmKGW2aHHuc4w> NUPS[JFPemWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm NWnCZpB4OjR2NkS4OFE>
U87 GBM MkXuSpVv[3Srb36gRZN{[Xl? M3G4d|ExOC93MECgUo0> NFvzSpA1QCCq NH:wZogyODBnIHX0bIFvd2x? MoHMTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 NVrTVIpTOjR2NkS4OFE>
RPE MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrPT4liOC5{L{CuOE8xNjhxMTFOwG0> MmfWNlQwPDhxN{KgbC=> NYrBd3duTE2VTx?= Ml\WbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> MkTqNlQ1PTZ4MEK=
HT29  NEPRS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\KdZlDOThyIH7N MXS3NkBp Mn6zTWM2OCCxZjCxPFAhdk1? M{HNNVI1OzZ6Mk[1
hMSCs NWC2Z2tXTnWwY4Tpc44hSXO|YYm= NYHJS5dTPi5{NTDuUS=> Mn:5NlQhcA>? M4LU[mROW09? Mmmwd5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= NIjYS24zPDNzMkO1Oi=>
Huh7  NULL[2RiTnWwY4Tpc44hSXO|YYm= NXjQ[lVuOC5zL{CuOU8yNjBizszN MlLwNlRp M{nTXJN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= MnjWNlQzPjl4N{K=
SKOV3 NXXPd|BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlA2NTJizszN NGnNXoEyOC9{ND:0PEBp NXLUTJVPTE2VTx?= M3vCNI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NGXIZWMzPDJ{M{iwNS=>
A2780 NVfKeFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\BSpoxNjB3LUKg{txO NYjtb|llOTBxMkSvOFghcA>? MonKSG1UVw>? M3eyVY1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NGfPb4EzPDJ{M{iwNS=>
SRA01/04  MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXVXWoxNjJizszN MnfTOFghcA>? NVG4OIhMTE2VTx?= NEniTY1{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NXrzbXpPOjRzNUe4O|g>
HLEB3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDxNE4zKM7:TR?= MYq0PEBp NG[4bHNFVVOR MXzzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MmLlNlQyPTd6N{i=
SRA01/04  M4HXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[2R|AvPC9yLkig{txO NHX3[4I1QCCq M1u2TWROW09? M{C4e4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mn;sNlQyPTd6N{i=
HLEB3 NUD1eVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiwMlQwOC56IN88US=> NYfIU21nPDhiaB?= NGXnbIxFVVOR M4q2Nolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnvZNlQyPTd6N{i=
HCT116 M1rNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HQcFAvOiEQvF2= MnTHNVIhcA>? M{PEboVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u Ml\WNlQyOjJ{M{G=
CA46 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HoUVMwPi9zMj:yOE81QCCwTR?= M4fGcVQ5KGh? MUjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh M17ON|I1ODZ2OUWx
PMNs M13jTGZ2dmO2aX;uJGF{e2G7 M2Hnb|MxKG6P M{iwZ|Q5KGh? MlnWbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 NGj5fGszOzl6OE[xOy=>
H1299 NEL3NIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vUTVHDqM7:TdMg NVr0c29tOjRxNEivO|IhcA>? NEThXXBmfGijbn;s MWrpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> NFvJb2QzOzlzNk[wPS=>
A549 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjpZVNvOC5{NT:wMlUwOSEQvF2= M1GyPFI1NzR6L{eyJIg> MmHZ[ZRp[W6xbB?= MX;pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MkT0NlM5Pjd7OUG=
H1299 M17OOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPCc|MxNjJ3L{CuOU8yKM7:TR?= MlO1NlQwPDhxN{KgbC=> MnzF[ZRp[W6xbB?= M{S4SolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? Ml7QNlM5Pjd7OUG=
A549 NWPJe3NiSXCxcITvd4l{KEG|c3H5 MlHONE42NzFizszN M3:x[lQ5KGh? M4\IU4V1cGGwb3y= MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmmyNlM5Pjd7OUG=
H1299 NYrWdIVPSXCxcITvd4l{KEG|c3H5 MlLtNE42NzFizszN M4C0ZVQ5KGh? MVrleIhidm:u MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M37QTVI{QDZ5OUmx
SUM149PT Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOyNk84NjVxMUCg{txO M2XFTFQ5KGh? M2rsWmROW09? MV;pcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? MmLFNlM4QTJ4M{i=
SUM190PT MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtWFI2OC9zMECvNlUxKG6P MXS0PEBp M1vOXmROW09? NH;B[nBqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? NIXacmQzOzd7Mk[zPC=>
HCT1 M3r5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPWNE4zNzFwMD:1MlAh|ryP MmrtNVIwOjRxM{[vOFghcA>? MkfobY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M2DxeVI{PzdyMECw
Lovo MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2e|AvOi9zLkCvOU4xKM7:TR?= NWHzPXp4OTJxMkSvN|YwPDhiaB?= NFX3U2hqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M4jHdVI{PzdyMECw
AGS MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4NVAvODF3LUGg{txO M13x[lczKGh? M{HZUIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NVuwb3pWOjN5NEWwNlQ>
Huh7 NWPoXVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjlOnEyKM7:TR?= NE\1d28zPCCq NWnXbIVlTE2VTx?= M3fOcZJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh M3nkUVI{PjR|OUOz
ECC1 NFLhdGhHfW6ldHnvckBCe3OjeR?= MXG1NFAhdk1? M3\VU|Uh\A>? NGnsU3JFVVOR NHXjb|FqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NE\6TXozOzV|MEe2PS=>
HEC1A MUTGeY5kfGmxbjDBd5NigQ>? NHjlTVY2ODBibl2= M3;UclUh\A>? MnX5SG1UVw>? NHjHcppqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NFXwPGkzOzV|MEe2PS=>
EN1 NInSNY5HfW6ldHnvckBCe3OjeR?= MlPxOVAxKG6P NX;SeWJTPSCm MoXxSG1UVw>? NYfiSIg3cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= M2DzVlI{PTNyN{[5
MFE296 M1T1VWZ2dmO2aX;uJGF{e2G7 M3TkVVUxOCCwTR?= NUHuW4pRPSCm NVrRTJY3TE2VTx?= M{P5SIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NXS2OGs3OjN3M{C3Olk>
HASMCs Moj3SpVv[3Srb36gRZN{[Xl? M{\nUlAuPTByIH7N M2e1cVYh\A>? MYDkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> MX:yN|UyQDR4Nx?=
U373 Mnn5SpVv[3Srb36gRZN{[Xl? NVnXfmJ3OC5{NT:wMlUwOSEQvF2= NH[yZ3AzPCCq MojKbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? M3rTN|I{PDd2MUex
ARN8  NV;sR|Z4TnWwY4Tpc44hSXO|YYm= Mk\jNE4xPS1{IN88US=> M37hfFI1KGh? NIHGeXVz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? Mm\uNlM1PzB3NEC=
MCF7 NYnOdnFoTnWwY4Tpc44hSXO|YYm= NG[xXZYxNjB3LUKg{txO MkO5NlQhcA>? MWTy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NEjvfIwzOzR5MEW0NC=>
H1299  NV7rdIplTnWwY4Tpc44hSXO|YYm= NF7uZYQxNjN|4pETNeKhyrWP NU\2bJAxOjRxNEigbC=> M1SyO2ROW09? M1ziPYlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= NUSyVpM1OjN2NkG5O|U>
H1299 M1zFZWZ2dmO2aX;uJGF{e2G7 NID4cmExNjVizszN M2DPZlQ5KGh? M{W5U2ROW09? MorpbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> MoDINlM1PjF7N{W=
H1299 NI[1WpRHfW6ldHnvckBCe3OjeR?= NU[4TFFuOC53IN88US=> NIHXVW01QCCq Ml7oSG1UVw>? NVP1VZFCcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= MUSyN|Q3OTl5NR?=
MG-63  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPBNE4{KM7:TR?= MUKxNk06PiCq NET3VYdFVVOR NXG2Sm51cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> Ml3wNlM1PTF6MUe=
LM8 NXPMWYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml32NE4{KM7:TR?= NGi3Wo0yOi17NjDo MUjEUXNQ MXjpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw NWPoOFQ2OjN2NUG4NVc>
K562 NUnKTVhZTnWwY4Tpc44hSXO|YYm= NYX3UmxlOC53IN88US=> M{fMTlI1KGh? M4HIWYV1cGGwb3y= MXzk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NFrVRZIzOzR|MEm1Oy=>
HEL MnjhSpVv[3Srb36gRZN{[Xl? MnzSNE42KM7:TR?= NW\uV4ZvOjRiaB?= NHHEVGVmfGijbn;s M1nHc4Rm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv M4\Ce|I{PDNyOUW3
HL60 NUfpZZFoSXCxcITvd4l{KEG|c3H5 NIfXTVkyKM7:TR?= MUCyOEBp Ml\2bY5lfWOnc9MgZ4VtdCCmZXH0bC=> NWXhOoJQOjN2MEC1NVk>
KG1 M2\IZmFxd3C2b4Ppd{BCe3OjeR?= MV2xJO69VQ>? NE\nVZgzPCCq MnXabY5lfWOnc9MgZ4VtdCCmZXH0bC=> M3LDbVI{PDByNUG5
Kazumi M3SxSGFxd3C2b4Ppd{BCe3OjeR?= NYDKTYUxOSEQvF2= M2TUXlI1KGh? NEnqOWxqdmS3Y3XzxsBk\WyuIHTlZZRp MWeyN|QxODVzOR?=
K562 M2DDSGFxd3C2b4Ppd{BCe3OjeR?= MoDFNUDPxE1? NYXuV2NOOjRiaB?= NWT0cW5vcW6mdXPld:Kh[2WubDDk[YF1cA>? Ml7qNlM1ODB3MUm=
THP1 NYLCPWhoSXCxcITvd4l{KEG|c3H5 MWixJO69VQ>? MmnwNlQhcA>? MmrKbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MmPLNlM1ODB3MUm=
SH-SY5Y MXvGeY5kfGmxbjDBd5NigQ>? NFXRemkzPTBibl2= NGLj[5YyPiCq M{K4R4Np[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= M2HlPFI{OzJ4NEKy
HEK293 MnnxSpVv[3Srb36gRZN{[Xl? MoXyNUDDvU4EoB?= MWexPEBpyqB? Mn\VbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? MWOyN|I5PDh2OB?=
HTK M1nF[WZ2dmO2aX;uJGF{e2G7 MoPsOFAxKG6P MXe3NkBp M4rDRYlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> NVfrcXNWOjN{OESwNFI>
HTK MV;GeY5kfGmxbjDBd5NigQ>? MnjFNVAxNThyMH7N MXK3NkBp MkSyZoxw[2u|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25? MlfnNlMzQDRyMEK=
Caco-2  MXvGeY5kfGmxbjDBd5NigQ>? NXzPOXJLOSEEtV5CpC=> MlLmNlQhcA>? Mmf3[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w NGLte|YzOzF7NUC3NC=>
HeLa M2i4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF25ZW8yODBibl2= NHLqcYgzPCCq NVGxUZR5TE2VTx?= MlfrTWM2OCCxZjCxNFBvVQ>? NFTH[VAzOzF4NUe0PC=>
HeLa MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi0NEBvVQ>? NUDpbFNjPDhiaB?= MYTEUXNQ NVrqTFY4UUN3MDDv[kA1OG6P NILDSYgzOzF4NUe0PC=>
HeLa MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES1VFYzOCCwTR?= MlLMO|IhcA>? MoniSG1UVw>? NGjmVXNKSzVyIH;mJFIxdk1? M1fNU|I{OTZ3N{S4
HeLa MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\u[2I2OTBxM{CvOVAhdk1? MUO3NkBp NEjF[XBFVVOR MVLpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= MnnCNlMyPjV5NEi=
MDA-MB-231 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDk[|IzPS12MECgcm0> NX:0dYIyPDhiaB?= MnnBTWM2OCCxZjCyOlMvOm6PwrC= M17Lb|I{ODV3MUm4
MCF-7  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuyOU01ODBibl2= NIrGOYw1QCCq NWi4RmptUUN3MDDv[kAzOjBwNH7N MYSyN|A2PTF7OB?=
ECC-1  NVTzPXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHzNVAxKG6P M2PLfVI1KGh? NIrLXZVmfGijbn;s M1m5SYlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= MXyyN|AzQDhyMx?=
HEC-1A M2DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrYN3N3OTByIH7N NEj0T3MzPCCq M2HzV4V1cGGwb3y= MXTpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? NUTZXlRvOjNyMki4NFM>
NHAC-kn NELKemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\WNVAwOTByL{WwNEBvVQ>? M4fZT|EzKGh? M1nwTWROW09? MX\JR|UxKG:oIEWwNI5O MlPUNlMxOTd6N{G=
A549 M4K0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCyOVAhdk1? M33ZNVYuPzJiaB?= NV3UPYRSTE2VTx?= MlLFZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> NF3IPWUzOjl7NEe4NC=>
MG-63 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTlN|AxKG6P MV[xNkBp MkTlSG1UVw>? MUjpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm M4jhfFIzPzl7M{O4
MG-63 NIL0OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvWXYd[OzByIH7N M4LCXVI1KGh? MVjEUXNQ MVXpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm NYHvPYZ4OjJ5OUmzN|g>
MG-63 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml63N|AxKG6P MVK0PEBp MojTSG1UVw>? M37wcYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? NFHCbnAzOjd7OUOzPC=>
HL60  NIPROoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[xOVAuOzVyIH7N M1WzeVI1KGh? Mni0bY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> M1fnbFIzPzV|N{O5
U937 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTVOIQyPTBvM{WwJI5O NUnjdnhJOjRiaB?= NV7PeG82cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? M4LsblIzPzV|N{O5
SCC-6 NGH1NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGyNFAuOzJyMDDuUS=> MVmxNk8zPC92ODDo MWfEUXNQ Mn;lbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2Pie|IzPTV{M{Kx
U87  NGrYRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWxWmVwOTByLUOwNEBv\w>? MViyOEBp NYn6SYMycW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= NUnDSY8xOjJ{N{C4OFk>
K562 NF;DSJpHfW6ldHnvckBCe3OjeR?= MYmxJO69VQ>? MmTTNVIhcA>? MYfEUXNQ NHPS[XBmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> MkXXNlIyPzlzOUi=
Reh NXvaPHU3TnWwY4Tpc44hSXO|YYm= NFjNUpUxNjNxMTFOwG0> NU\kPYdlOTJiaB?= NXLkTHJITE2VTx?= Ml3k[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M4q5dVIzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

Related Antibodies

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID